Explore our validated generic peptide APIs and metabolic receptor agonists available for immediate commercial supply, custom scaling, and formulation development.
Thymosin Alpha 1 (CAS 62304-98-7) is an acidic 28-amino acid synthetic pleiotropic immunomodulator naturally cleaved from prothymosin alpha. In modern commercial manufacturing, procuring pharmaceutical-grade Tα1 requires addressing systemic chemical synthesis challenges, sequence-specific degradation routes, and global supply chain vulnerabilities.
With five glutamic acid (Glu) and three aspartic acid (Asp) residues, Tα1 is exceptionally prone to α-to-β aspartyl transpeptidation and D-stereoisomer formation during solid-phase elongation. Thinheal's proprietary low-racemization cleavage protocols and pseudoproline dipeptide building blocks suppress D-[Asp15]-Tα1 and D-[Glu25]-Tα1 diastereomeric impurities to < 0.10%.
Standard solid phase peptide synthesis utilizes trifluoroacetic acid (TFA) for deprotection, leaving residual TFA counter-ions that are cytotoxic in clinical parenteral preparations. Thinheal incorporates a dedicated multi-stage ion exchange chromatography step to yield high-affinity Thymosin Alpha 1 Acetate with residual TFA < 0.2% and acetate content within stoichiometric limits (4.0% – 8.0%).
Because Thymosin Alpha 1 acts on Toll-like receptors (TLR2, TLR9) to trigger dendritic cell activation, foreign bacterial endotoxins directly confound clinical bioassays and cause fatal pyrogenic reactions. Our closed lyophilization lines maintain strict bioburden limits with bacterial endotoxin levels verified under < 5 EU/mg (or < 1.0 EU/mg upon custom validation).
Primary Amino Acid Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH.
Molecular Formula: C129H215N33O45 | Monoisotopic Mass: 3106.54 Da | Chemical CAS Number: 62304-98-7.
Thinheal's industrialized chemical synthesis guarantees absolute 100% N-terminal acetylation (Ac-Ser1) without under-acetylated or deamidated (Desamido-Asn28) side products.
Global market dynamics for Thymosin Alpha 1 have shifted from niche oncology adjuvants to mainstream commercial production for chronic viral hepatitis, chemo-protective regimens, sepsis rescue, and vaccine enhancement. Strategic buyers require transparency on volumetric tiers, counter-ion adjustments, and analytical release costs.
| Analytical Parameter | Validation Testing Method | Thinheal Commercial Release Standard | Compliance Reference |
|---|---|---|---|
| Appearance | Visual Inspection | White to off-white lyophilized amorphous powder | Ph. Eur. / USP General |
| Chemical Identity (MS) | ESI-MS / HR-MS (Electrospray) | 3108.3 ± 1.0 Da (Monoisotopic / Average MW) | ICH Q6A / USP ⟨733⟩ |
| Chromatographic Purity | RP-HPLC (C18 Column, Dual Wavelength) | ≥ 98.5% (Standard) / ≥ 99.2% (Pharma Grade) | In-house validated HPLC |
| Single Largest Impurity | Reversed-Phase Gradient HPLC | ≤ 0.5% (Total unknown impurities ≤ 1.0%) | ICH Q3A(R2) Impurities |
| D-Amino Acid Racemization | Chiral GC-MS / Hydrolysis | ≤ 0.15% D-Asp, ≤ 0.10% D-Glu | Chiral Resolution Release |
| Peptide Net Content | Quantitative Amino Acid Analysis (AAA) | ≥ 80.0% – 88.0% | Absolute Nitrogen/AAA |
| Counter-Ion Content | Ion Chromatography (IC) | Acetate: 4.0% – 8.0% | Residual TFA ≤ 0.2% | USP ⟨591⟩ / IC Assays |
| Moisture (Water Content) | Karl Fischer Coulometric Titration | ≤ 5.0% (Controlled lyophilization) | USP ⟨921⟩ Method 1c |
| Bacterial Endotoxins | Kinetic Turbidimetric / LAL Test | ≤ 5.0 EU/mg (Injectable-grade batch release) | USP ⟨85⟩ / EP 2.6.14 |
| Residual Solvents | Headspace Gas Chromatography (GC-HS) | MeCN ≤ 410 ppm, DMF ≤ 880 ppm, DCM ≤ 600 ppm | ICH Q3C(R8) Solvents |
Quote on Req.
Designed for in vitro screening, assay validation, and non-GLP exploratory toxicology. Ships with basic HPLC + ESI-MS CoA.
Scale Discount
Formulation optimization, animal efficacy models, and pre-formulation stability testing. Includes residual solvent profiling.
Contract Volume
Engineered for IND filings, Phase I/II clinical trials, and pilot batch vial filling. Full CMC documentation support available.
Annual Supply
Commercial market manufacturing under multi-ton synthesis capacity. Dedicated reactor trains, audit rights, and regulatory DMF.
Across global healthcare markets, Thymosin Alpha 1 is leveraged for its ability to reprogram both innate and adaptive immunity without inducing toxic inflammatory cytokine storms. Sourcing managers align procurement grades with specific localized clinical pathways.
Used routinely in East Asian and European oncological protocols as an adjuvant to counter chemotherapy-induced lymphopenia. Tα1 stimulates hematopoietic stem cell differentiation into CD4+ helper and CD8+ cytotoxic T lymphocytes, while concurrently reversing chemotherapy-induced immunosuppression. When combined with PD-1/PD-L1 checkpoint inhibitors, Tα1 enhances tumor infiltration of active effector cells.
In authorized territories across over 30 countries, Thymosin Alpha 1 is licensed for the management of chronic Hepatitis B virus (HBV) with viral replication. Tα1 increases Class I HLA antigen expression on virally infected hepatocytes, allowing natural killer (NK) cells and virus-specific CTLs to clear intracellular viral reservoirs, contributing to HBeAg seroconversion and sustained virologic response.
Severe sepsis often induces immune paralysis marked by massive apoptosis of splenic lymphocytes and down-regulation of HLA-DR on monocytes. Multicenter clinical evaluations show early administration of pharmaceutical-grade Tα1 reverses monocyte anergy, reduces secondary nosocomial infections, and reduces 28-day mortality rates among septic shock patients.
International drug substance procurement demands bulletproof regulatory dossiers, analytical validation packages, and cold-chain supply security. Hangzhou Thinheal Pharma-Tech Co., Ltd. provides comprehensive technical backing for your filings.
CTD-format Drug Master Files (DMF) prepared for US FDA, EDQM ASMF filings in Europe, and NMPA registration dossiers in China. Letter of Authorization (LoA) provided directly to filing sponsors.
Real-time long-term (-20°C ± 5°C) and accelerated (5°C ± 3°C / 60% RH) stability programs tracking related substances, racemization, moisture content, and peptide titer over 36 months.
Validated temperature-controlled shipping configurations with dry ice or phase-change materials, integrated real-time USB/GPS temperature data loggers, and expedited customs clearance corridors.
Direct access to dedicated multilingual technical sales managers covering the Americas, European Union, CIS territories, and Asia-Pacific to streamline contracts and audits.
As environmental regulations tighten and continuous processing takes center stage in biopharma, Thinheal is modernizing peptide API manufacturing through process intensification, green chemistry, and modified immunomodulators.
Traditional peptide synthesis relies heavily on hazardous solvents like DMF and NMP. Thinheal's pilot line integrates alternative greener reaction media (e.g., 2-MeTHF, cyclopentyl methyl ether) and recycling distillation loops, slashing the Process Mass Intensity (PMI) by 45% while maintaining exceptional coupling efficiency across all 28 cycles.
To break batch-to-batch variation bottlenecks, our R&D center is piloting Continuous Automated Flow SPPS. Microfluidic-assisted coupling at controlled elevated temperatures (60°C – 75°C) reduces individual amino acid incorporation cycle times from 60 minutes to under 8 minutes, dramatically shortening manufacturing turnaround times.
Native Thymosin Alpha 1 exhibits a rapid plasma clearance (half-life ∼ 2 hours). In collaboration with drug delivery pioneers, Thinheal CDMO explores site-specific PEGylation, fatty-acid acylation (similar to GLP-1 platforms), and albumin-binding tags to create second-generation immunomodulators with once-weekly sustained therapeutic pharmacokinetics.
Get direct, transparent answers to the questions sourcing managers, formulation scientists, and quality assurance auditors ask most frequently during technical qualification.
Thinheal supplies Thymosin Alpha 1 API at a validated minimum RP-HPLC purity of ≥ 98.5%, with high-purity pharmaceutical grades exceeding ≥ 99.2%. Single largest individual impurities are strictly restricted to ≤ 0.5%, and total unknown related substances are held under ≤ 1.0%. Every production lot includes verified chromatographic traces demonstrating baseline peak separation.
HPLC purity indicates the percentage of target peptide molecule relative to all UV-absorbing peptide-related substances in the sample. In contrast, net peptide content (or peptide titer) measures the actual mass percentage of peptide versus non-peptide components, which naturally include acetate counter-ions (typically 4.0% – 8.0%), crystalline/bound water (2.0% – 5.0%), and trace salts. Dosing calculations in formulations should always be calculated using the net peptide content determined by Quantitative Amino Acid Analysis (AAA).
Yes. Parenteral formulations require strict endotoxin controls to prevent pyrogen-induced cytokine shock. Our dedicated downstream processing, ultrafiltration membranes, and Class A/C cleanroom lyophilizers consistently yield injectable-grade bulk powder with bacterial endotoxins < 5.0 EU/mg. For specialized intra-articular or neonatal investigational lines, custom sub-lots can be validated down to < 1.0 EU/mg via kinetic chromogenic LAL assays.
Thymosin Alpha 1 contains multiple aspartic acid (Asp) and glutamic acid (Glu) residues susceptible to racemization during standard Fmoc-SPPS coupling conditions. We employ sterically hindered OxymaPure/DIC coupling agents, optimize basic wash intervals, and integrate pre-synthesized pseudoproline dipeptides at critical sequence junctions. Chiral amino acid gas chromatography-mass spectrometry (GC-MS) confirms total D-Asp and D-Glu residues remain strictly ≤ 0.15% in release materials.
Standard commercial shipments include a comprehensive Batch Certificate of Analysis (CoA) containing analytical release data for HPLC purity, ESI-MS molecular weight verification, net peptide content, acetate/TFA content, water content (Karl Fischer), residual solvents (GC-HS), heavy metals, bioburden, and endotoxins. In addition, customers can request our Safety Data Sheet (SDS), BSE/TSE-free certification, elemental impurity declarations (ICH Q3D), and Drug Master File (DMF) Letters of Authorization.
Bulk lyophilized Thymosin Alpha 1 powder must be preserved desiccated at -20°C ± 5°C, protected from moisture and intense light exposure. Under these conditions, the powder remains stable for a retest period of at least 24 to 36 months. When reconstituting, allow the sealed container to equilibrate to room temperature before opening to avoid atmospheric condensation. Reconstitute in sterile bacteriostatic water for injection or sterile saline, and avoid vigorous vortexing to prevent mechanical shear aggregation.
In addition to Thymosin Alpha 1, Hangzhou Thinheal Pharma-Tech manufactures an extensive portfolio of nootropics, tissue repair factors, growth hormone secretagogues, and high-barrier commercial APIs.
Contact Hangzhou Thinheal Pharma-Tech Co., Ltd. for direct quotation packages, technical specifications, and bulk reserve contracts. Our dedicated international desk replies within 24 hours with project-specific documentation.
Thin